The results suggest that FGFR1-activated PI3K/AKT/mTOR and JAK/STAT3 signaling pathways may promote NB development and ponatinib-induced inhibition of FGFR1 signaling contributes to its anti-tumor effects. The gene discussed is STAT3; the disease is neoplasm.